Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soleno Therapeutics ( (SLNO) ) has shared an announcement.
On October 13, 2025, Soleno Therapeutics announced the appointment of Mark W. Hahn to its Board of Directors and Audit Committee, expanding the Board to seven members. Mr. Hahn brings nearly 30 years of financial and operational leadership experience in the life sciences sector, having previously served as CFO for several companies, including Verona Pharma and Dova Pharmaceuticals, where he played key roles in product launches and strategic transactions. His appointment is expected to strengthen Soleno’s commercial efforts, particularly in maximizing the reach of its product VYKAT XR for Prader-Willi syndrome.
The most recent analyst rating on (SLNO) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Underperform.
Soleno Therapeutics shows high risk due to its lack of revenue and reliance on external financing. However, it maintains a solid equity base and is experiencing positive technical momentum, suggesting speculative interest. The valuation is typical for an early-stage biotech, with potential upside reliant on successful R&D outcomes.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR, is an oral treatment for hyperphagia in individuals with Prader-Willi syndrome, approved by the FDA in March 2025.
Average Trading Volume: 1,780,687
Technical Sentiment Signal: Buy
Current Market Cap: $3.39B
See more insights into SLNO stock on TipRanks’ Stock Analysis page.